A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
NCT02509039
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class
Stopped
Replaced it with another clinical trial.
Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG:
CC-122
Sponsor
Celgene